Real Life of Aflibercept In FraNce: oBservatiOnnal Study in Wet AMD

Sponsor
Bayer
Study ID
NCT02279537
Status
Completed

Conditions

  • Wet Macular Degeneration

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to collect real-life data on patients with wet age related macular degeneration (AMD) for whom treatment with Eylea was initiated

Key Dates

Start date
Jan 2, 2014
Status verified
Nov 2023
Primary completion
Apr 17, 2019
Completion
Apr 17, 2019

Study Design

Enrollment
593 participants (actual)

Arms

  • Arm: Cohort 1
    According to the recommendations of the Summary of Product Characteristics (SmPC)

Primary Outcome Measure

Change in the measurement of best-corrected visual acuity (BCVA) from baseline to 12 months. [ Time Frame: Baseline to 12 months ]

Related Studies